FDA
-
-
-
-
-
-
-
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
-
-
-
-
-
-
-
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
-
-
-
-
-
-
-
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
-
-
-
-
-
-
-
QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA
-
-
-
-
-
-
-
QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
-
-
-
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

